Phenytoin-induced dyskinesia: a case report.
Adverse drug reaction
Dyskinesia
Phenytoin
Seizures
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
21 Jul 2023
21 Jul 2023
Historique:
received:
05
03
2023
accepted:
09
06
2023
medline:
24
7
2023
pubmed:
21
7
2023
entrez:
20
7
2023
Statut:
epublish
Résumé
Dyskinesia is a movement disorder categorized by involuntary movement of muscle. Although dyskinesia can be brought on by taking medications, it can also be a symptom of a variety of diseases. Antiepileptic drug-induced involuntary movements have been well researched. Rare reports have been made for dyskinesia, a type of dystonia caused by phenytoin. The mechanism of its occurrence must be succinctly studied. A 53-year-old Asian patient taking phenytoin (100 mg twice daily) experienced symptoms of perioral muscle involuntary movement, impaired speech, and generalized tremors and was admitted to the hospital. Brain magnetic resonance imaging showed significant development of encephalomalacia and porencephaly. The serum phenytoin levels were in the toxic range (33 g/ml). These were suggestive of phenytoin-induced dyskinesia. Levetiracetam and clonazepam were initiated, and the patient showed significant improvement in the symptoms. This case presented a substantial reference value for the differential diagnosis and treatment prognosis of phenytoin-induced dyskinesia. The phenytoin-induced dyskinesia in this patient was successfully reversed with prompt identification and treatment. According to the case study's findings, such people may benefit from periodic therapeutic drug monitoring.
Sections du résumé
BACKGROUND
BACKGROUND
Dyskinesia is a movement disorder categorized by involuntary movement of muscle. Although dyskinesia can be brought on by taking medications, it can also be a symptom of a variety of diseases. Antiepileptic drug-induced involuntary movements have been well researched. Rare reports have been made for dyskinesia, a type of dystonia caused by phenytoin. The mechanism of its occurrence must be succinctly studied.
CASE PRESENTATION
METHODS
A 53-year-old Asian patient taking phenytoin (100 mg twice daily) experienced symptoms of perioral muscle involuntary movement, impaired speech, and generalized tremors and was admitted to the hospital. Brain magnetic resonance imaging showed significant development of encephalomalacia and porencephaly. The serum phenytoin levels were in the toxic range (33 g/ml). These were suggestive of phenytoin-induced dyskinesia. Levetiracetam and clonazepam were initiated, and the patient showed significant improvement in the symptoms.
CONCLUSION
CONCLUSIONS
This case presented a substantial reference value for the differential diagnosis and treatment prognosis of phenytoin-induced dyskinesia. The phenytoin-induced dyskinesia in this patient was successfully reversed with prompt identification and treatment. According to the case study's findings, such people may benefit from periodic therapeutic drug monitoring.
Identifiants
pubmed: 37475012
doi: 10.1186/s13256-023-04033-6
pii: 10.1186/s13256-023-04033-6
pmc: PMC10360218
doi:
Substances chimiques
Phenytoin
6158TKW0C5
Anticonvulsants
0
Levetiracetam
44YRR34555
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
313Informations de copyright
© 2023. The Author(s).
Références
Neurologia. 2013 Apr;28(3):193-4
pubmed: 22595500
Neurology. 1980 Dec;30(12):1333-4
pubmed: 7192814
Arch Neurol. 1994 Jul;51(7):702-4
pubmed: 8018044
Mov Disord. 1993;8(1):19-27
pubmed: 8419804
Neurology. 1984 Dec;34(12):1600-1
pubmed: 6504332
Oman Med J. 2010 Jan;25(1):17-21
pubmed: 22125692
Neurology. 1995 Jan;45(1):185-7
pubmed: 7824115
Gen Pharmacol. 1996 Oct;27(7):1091-7
pubmed: 8981053
Ann Neurol. 1986 Aug;20(2):171-84
pubmed: 2428283
J Neurol Neurosurg Psychiatry. 1975 Mar;38(3):225-31
pubmed: 239101
Food Chem Toxicol. 2020 Aug;142:111393
pubmed: 32376339
Arq Neuropsiquiatr. 1999 Jun;57(2B):356-60
pubmed: 10450338
Mov Disord. 1996 Jan;11(1):111-4
pubmed: 8771085